Premium
Stereotactic body radiotherapy for patients with small hepatocellular carcinoma ineligible for resection or ablation therapies
Author(s) -
Kimura Tomoki,
Aikata Hiroshi,
Takahashi Shigeo,
Takahashi Ippei,
Nishibuchi Ikuno,
Doi Yoshiko,
Kenjo Masahiro,
Murakami Yuji,
Honda Yohji,
Kakizawa Hideaki,
Awai Kazuo,
Chayama Kazuaki,
Nagata Yasushi
Publication year - 2015
Publication title -
hepatology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.123
H-Index - 75
eISSN - 1872-034X
pISSN - 1386-6346
DOI - 10.1111/hepr.12359
Subject(s) - medicine , hepatocellular carcinoma , confidence interval , ablation , radiofrequency ablation , radiation therapy , radiosurgery , incidence (geometry) , nuclear medicine , radiology , physics , optics
Aim To evaluate the efficacy and safety of stereotactic body radiotherapy ( SBRT ) in patients with small hepatocellular carcinoma ( HCC ) who were ineligible for resection or ablation therapies. Methods Overall, 65 patients with 74 HCC (median tumor size, 16 mm) were enrolled. They were treated at the prescribed dose of 48 Gy in four fractions at the isocenter. C hild– T urcotte– P ugh ( CTP ) scoring was used to classify 56 and nine patients into classes A and B, respectively. Local progression was defined as irradiated tumor growth on a dynamic computed tomography follow up. The median follow‐up period was 26 months. Tumor responses were assessed according to the modified R esponse E valuation C riteria in S olid T umors. Treatment‐related toxicities were evaluated according to the C ommon T erminology C riteria for A dverse E vents version 4.0. Results The 2‐year overall survival, progression‐free survival and local control rates were 76.0% (95% confidence interval [ CI ], 65.4–86.7%), 40.0% (95% CI , 27.6–52.3%) and 100% (95% CI , 100%), respectively. At 6–12 months after SBRT , grade 3 or higher toxicities was observed in 15 (23.1%) patients. The incidence of grade 3 or higher toxicities was higher in CTP class B than in class A ( P = 0.0127). Conclusion SBRT was effective and relatively safe for patients with small HCC who were ineligible for resection or ablation therapies.